Lee Ainslie Maverick Capital
Lee Ainslie is the founder of Maverick Capital, a long/short equity firm that emerged from the Tiger Management network of investors. Maverick is known for fundamental research, sector specialization among teams, and a classic hedge fund long/short structure. Ainslie’s firm remains a reference name among so-called Tiger Cub managers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OSH
Oak Street Health, Inc.
OSH
|
+$150M |
| 2 |
Visa
V
|
+$84.7M |
| 3 |
TG Therapeutics
TGTX
|
+$71.1M |
| 4 |
Mastercard
MA
|
+$70.2M |
| 5 |
ATVI
Activision Blizzard
ATVI
|
+$66.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coupang
CPNG
|
+$279M |
| 2 |
Centene
CNC
|
+$257M |
| 3 |
ONEM
1Life Healthcare
ONEM
|
+$74.1M |
| 4 |
International Flavors & Fragrances
IFF
|
+$69M |
| 5 |
Seer Inc
SEER
|
+$66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 43.56% |
| 2 | Technology | 17.09% |
| 3 | Healthcare | 11.19% |
| 4 | Communication Services | 9.35% |
| 5 | Financials | 6.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Sempra
SRE
$54.2B
| – | – |
-16,938
| Closed | -$1.07M |
|
602
Stratasys
SSYS
$692M
| – | – |
-30,651
| Closed | -$660K |
|
603
Scorpio Tankers
STNG
$3.93B
| – | – |
-32,663
| Closed | -$606K |
|
604
Constellation Brands
STZ
$23.2B
| – | – |
-41,472
| Closed | -$8.74M |
|
605
Skyworks Solutions
SWKS
$10.1B
| – | – |
-9,461
| Closed | -$1.56M |
|
606
Sysco
SYY
$40.2B
| – | – |
-5,504
| Closed | -$432K |
|
607
AT&T
T
$173B
| – | – |
-96,391
| Closed | -$1.97M |
|
608
Trip.com Group
TCOM
$29B
| – | – |
-12,102
| Closed | -$372K |
|
609
Telephone and Data Systems
TDS
$3.87B
| – | – |
-16,226
| Closed | -$316K |
|
610
Teledyne Technologies
TDY
$29.5B
| – | – |
-590
| Closed | -$253K |
|
611
Teradyne
TER
$58.7B
| – | – |
-12,649
| Closed | -$1.38M |
|
612
Truist Financial
TFC
$61.6B
| – | – |
-10,519
| Closed | -$617K |
|
613
Teleflex
TFX
$5.88B
| – | – |
-3,913
| Closed | -$1.47M |
|
|
TMHC
614
DELISTED
Taylor Morrison
TMHC
| – | – |
-15,098
| Closed | -$389K |
|
615
TripAdvisor
TRIP
$1.17B
| – | – |
-4,689
| Closed | -$159K |
|
616
Trimble
TRMB
$14B
| – | – |
-2,707
| Closed | -$223K |
|
617
T. Rowe Price
TROW
$23.8B
| – | – |
-1,849
| Closed | -$364K |
|
618
Tronox
TROX
$888M
| – | – |
-7,675
| Closed | -$189K |
|
619
Tractor Supply
TSCO
$18.2B
| – | – |
-33,615
| Closed | -$1.36M |
|
620
United Therapeutics
UTHR
$22B
| – | – |
-4,361
| Closed | -$805K |
|
621
Vulcan Materials
VMC
$35.8B
| – | – |
-2,550
| Closed | -$431K |
|
|
VNET
622
VNET Group
VNET
$1.91B
| – | – |
-811
| Closed | -$14K |
|
|
VRNT
623
DELISTED
Verint Systems
VRNT
| – | – |
-3,354
| Closed | -$150K |
|
624
Vertex Pharmaceuticals
VRTX
$139B
| – | – |
-18,052
| Closed | -$3.27M |
|
625
Vishay Intertechnology
VSH
$4.85B
| – | – |
-17,762
| Closed | -$357K |
|
Similar funds
Lee Ainslie's Q4 2021 Portfolio in Review
As of Q4 2021, Lee Ainslie held 681 positions worth $8.85B, down 11% from $9.92B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Lee Ainslie withdrew a net $1.02B in Q4 2021, closing 373 positions and reducing 179 holdings. Its most notable exit was Centene, an estimated $257M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 44% of assets, up from 41% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Lee Ainslie opened a new position in Rivian worth $51.8M.
- Lee Ainslie's largest Q4 2021 buy was Rivian: 500,000 shares worth $51.8M.
- Lee Ainslie added most to Oak Street Health, Inc. in Q4 2021, an estimated $150M increase.
- Lee Ainslie's biggest Q4 2021 reduction was Coupang, cutting an estimated $279M.
- Lee Ainslie fully exited Centene in Q4 2021, selling an estimated $257M.
- Lee Ainslie's ten largest holdings make up 57% of its $8.85B portfolio in Q4 2021.
- Lee Ainslie opened 56 new positions and closed 373 in Q4 2021.
- Lee Ainslie's portfolio value fell 11% quarter-over-quarter to $8.85B.
Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.